Diagnostic and therapeutic approach to persistent abdominal pain beyond irritable bowel syndrome

被引:5
作者
Coffin, Pr. Benoit [1 ,2 ]
Duboc, Henri [1 ,2 ]
机构
[1] Univ Paris Cite, Equipe PIMS, Paris, France
[2] Hop Louis Mourier, AP HP, Gastroenterol Unit, DMU Esprit, Colombes, France
关键词
EHLERS-DANLOS-SYNDROME; FUNCTIONAL GASTROINTESTINAL DISORDERS; WALL PAIN; LAPAROSCOPIC ADHESIOLYSIS; HEREDITARY ANGIOEDEMA; CLINICAL-FEATURES; SYMPTOMS; COMMON; CLASSIFICATION; INVOLVEMENT;
D O I
10.1111/apt.17064
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Persistent abdominal pain (PAP) poses substantial challenges to patients, physicians and healthcare systems. The possible aetiologies of PAP vary widely across organ systems, which leads to extensive and repetitive diagnostic testing that often fails to provide satisfactory answers. As a result, widely recognised functional disorders of the gut-brain interaction, such as irritable bowel syndrome and functional dyspepsia, are often diagnosed in patients with PAP. However, there are a number of less well-known differential diagnoses that deserve consideration. Aim To provide a comprehensive update on causes of PAP that are relatively rare in occurrence. Methods A literature review on the diagnosis and management of some less well-known causes of PAP. Results Specific algorithms for the diagnostic work-up of PAP do not exist. Instead, appropriate investigations tailored to patient medical history and physical examination findings should be made on a case-by-case basis. After a definitive diagnosis has been reached, some causes of PAP can be effectively treated using established approaches. Other causes are more complex and may benefit from a multidisciplinary approach involving gastroenterologists, pain specialists, psychologists and physiotherapists. This list is inclusive but not exhaustive of all the rare or less well-known diseases potentially associated with PAP. Conclusions Persistent abdominal pain (PAP) is a challenging condition to diagnose and treat. Many patients undergo repeated diagnostic testing and treatment, including surgery, without achieving symptom relief. Increasing physician awareness of the various causes of PAP, especially of rare diseases that are less well known, may improve patient outcomes.
引用
收藏
页码:419 / 435
页数:17
相关论文
共 105 条
  • [1] Diagnosis of mast cell activation syndrome: a global "consensus-2"
    Afrin, Lawrence B.
    Ackerley, Mary B.
    Bluestein, Linda S.
    Brewer, Joseph H.
    Brook, Jill B.
    Buchanan, Ariana D.
    Cuni, Jill R.
    Davey, William P.
    Dempsey, Tania T.
    Dorff, Shanda R.
    Dubravec, Martin S.
    Guggenheim, Alena G.
    Hindman, Kimberly J.
    Hoffman, Bruce
    Kaufman, David L.
    Kratzer, Stephanie J.
    Lee, Theodore M.
    Marantz, Mindy S.
    Maxwell, Andrew J.
    McCann, Kelly K.
    McKee, Dwight L.
    Otto, Laurie Menk
    Pace, Laura A.
    Perkins, Dahra D.
    Radovsky, Laurie
    Raleigh, Mary S.
    Rapaport, Sonia A.
    Reinhold, Emma J.
    Renneker, Mark L.
    Robinson, William A.
    Roland, Aaron M.
    Rosenbloom, E. Scott
    Rowe, Peter C.
    Ruhoy, Ilene S.
    Saperstein, David S.
    Schlosser, David A.
    Schofield, Jill R.
    Settle, Janet E.
    Weinstock, Leonard B.
    Wengenroth, Martina
    Westaway, Mark
    Xi, Shijun Cindy
    Molderings, Gerhard J.
    [J]. DIAGNOSIS, 2021, 8 (02) : 137 - 152
  • [2] Mast cell activation syndromes
    Akin, Cem
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 140 (02) : 349 - 355
  • [3] [Anonymous], 2021, GIVLAARI
  • [4] [Anonymous], 2020, GIVLAARI CANADA
  • [5] [Anonymous], 2021, GIVLAARI SUMMARY PRO
  • [6] [Anonymous], 2021, Obtained manufacturing and marketing approval for "Giblari"for the treatment of acute hepatic porphyria press release
  • [7] [Anonymous], 2020, Alnylam announces approval of GIVLAARI (givosiran) in Brazil for the treatment of acute hepatic porphyria (AHP) in adults press release
  • [8] [Anonymous], 2019, SYSTEMIC MASTOCYTOSI
  • [9] Azizi Zahra, 2014, Middle East J Dig Dis, V6, P5
  • [10] Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
    Balwani, Manisha
    Sardh, Eliane
    Ventura, Paolo
    Peiro, Paula Aguilera
    Rees, David C.
    Stoelzel, Ulrich
    Bissell, D. Montgomery
    Bonkovsky, Herbert L.
    Windyga, Jerzy
    Anderson, Karl E.
    Parker, Charles
    Silver, Samuel M.
    Keel, Sioban B.
    Wang, Jiaan-Der
    Stein, Penelope E.
    Harper, Pauline
    Vassiliou, Daphne
    Wang, Bruce
    Phillips, John
    Ivanova, Aneta
    Langendonk, Janneke G.
    Kauppinen, Raili
    Minder, Elisabeth
    Horie, Yutaka
    Penz, Craig
    Chen, Jihong
    Liu, Shangbin
    Ko, John J.
    Sweetser, Marianne T.
    Garg, Pushkal
    Vaishnaw, Akshay
    Kim, Jae B.
    Simon, Amy R.
    Gouya, Laurent
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (24) : 2289 - 2301